Lansen Pharma (503 HK): 27th November Scheme Vote
It's an okay premium to last close, but enough for the Offer to get up. Trading wide at a 7.1%/51.1% gross/annualised spread. If small-cap,...
Lansen Pharma (503 HK): The Chairman Makes An Offer
There's enough here for the Offer to get up. Terms have been declared final. Long-term shareholders would have also benefitted from the HK$1.55...
Lansen Pharm (503 HK): Here Is Your Exit
A special dividend is a pretty good outcome. On a 24x ex-dividend basis - and with the "event" not announced - I'm disinclined to hold shares here.
Lansen Pharma (503 HK): This Is Still A Buy
The privatisation of its parent implied a value of $4.28/share for Lansen. I think this still has more to run from here.
Lansen Pharma (503 HK): This Is A Buy
Net cash accounts for 84.6% of market cap. The offer for its parent implied a value of $3.82/share. The core underlying business of Lansen was...
No more insights